Exponent, Inc. (EXPO) To Go Ex-Dividend on December 4th

Exponent, Inc. (NASDAQ:EXPO) declared a quarterly dividend on Thursday, October 29th. Shareholders of record on Friday, December 4th will be given a dividend of $0.31 per share by the business services provider on Friday, December 18th. This represents a $1.24 dividend on an annualized basis and a yield of 1.5%. The ex-dividend date of this dividend is Friday, December 4th.

Exponent has increased its dividend payment by an average of 0.1% annually over the last three years and has raised its dividend every year for the last 12 years. Exponent has a dividend payout ratio of 57.9% meaning its dividend is sufficiently covered by earnings. Research analysts expect Exponent to earn $2.67 per share next year, which means the company should continue to be able to cover its $1.24 annual dividend with an expected future payout ratio of 46.4%.

Exponent Price Performance

EXPO stock opened at $80.26 on Friday. The firm has a 50 day simple moving average of $70.19 and a two-hundred day simple moving average of $66.64. The stock has a market cap of $3.82 billion, a PE ratio of 34.59 and a beta of 0.69. Exponent has a one year low of $51.91 and a one year high of $83.18.

Exponent (NASDAQ:EXPO) last posted its quarterly earnings data on Thursday, October 29th. The business services provider reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.60 by $0.04. Exponent had a net margin of 17.40% and a return on equity of 33.82%. The firm had revenue of $173.73 million for the quarter, compared to analysts’ expectations of $149.64 million. During the same quarter last year, the company posted $0.55 EPS. The business’s quarterly revenue was up 11.7% on a year-over-year basis. On average, research analysts expect that Exponent will post 2.31 EPS for the current fiscal year.

Insiders Place Their Bets

In other Exponent news, CEO Catherine Corrigan sold 1,707 shares of the business’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $66.28, for a total value of $113,139.96. Following the completion of the sale, the chief executive officer directly owned 129,108 shares of the company’s stock, valued at $8,557,278.24. The trade was a 1.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.70% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Chicago Partners Investment Group LLC purchased a new stake in Exponent during the 3rd quarter valued at $226,000. Covestor Ltd increased its position in shares of Exponent by 10.3% in the third quarter. Covestor Ltd now owns 2,050 shares of the business services provider’s stock valued at $134,000 after acquiring an additional 192 shares during the period. Bridge City Capital LLC increased its position in shares of Exponent by 21.6% in the third quarter. Bridge City Capital LLC now owns 49,231 shares of the business services provider’s stock valued at $3,221,000 after acquiring an additional 8,729 shares during the period. Vise Technologies Inc. bought a new position in shares of Exponent during the third quarter valued at about $343,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in shares of Exponent during the third quarter valued at about $216,000. Hedge funds and other institutional investors own 92.37% of the company’s stock.

About Exponent

Exponent, Inc is a science and engineering consulting company that helps clients investigate complex technical issues, manage risks, and develop solutions. Its consultants work across disciplines including engineering, materials science, biomechanics, human factors, environmental science, health, data sciences, and economics.

The company provides failure analysis, product safety and testing, accident reconstruction, environmental and health assessments, regulatory support, and expert testimony.